Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
This page contains brief information about recombinant human papillomavirus (HPV) bivalent vaccine and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials.
Use in Cancer
Recombinant human papillomavirus (HPV) bivalent vaccine is approved to prevent some conditions caused by certain types of HPV. It is used in females aged 9 to 25 years to prevent the following:
More About Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Human Papillomavirus (HPV) Vaccine - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
HPV and Cancer - Information about the use of this drug to prevent cancer.
Human Papillomavirus (HPV) Vaccines - Information about the use of this drug to prevent cancer.
Cancer Vaccines - Information about the use of this drug to prevent cancer.
Clinical Trials Accepting Patients
Find Clinical Trials for Human Papillomavirus 16/18 L1 Virus-like Particle/as04 Vaccine - Check for trials from NCI's list of cancer clinical trials now accepting patients.